{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:09:51Z","timestamp":1788829791562,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi-Aventis Denmark A\/S","award":["-"],"award-info":[{"award-number":["-"]}]},{"name":"Applied Economics and Health Research"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>We aimed to investigate trends in low-density lipoprotein cholesterol (LDL-C) goal achievement (LDL-C&lt;1.8 mmol\/L, equivalent to 70 mg\/dL), initiation of lipid-lowering therapy (LLT) and changes in LLT intensity in individuals with atherosclerotic cardiovascular disease (ASCVD) at very high risk of recurrent cardiovascular disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A cohort study design was used including individuals with incident ASCVD and LDL-C\u22651.8 mmol\/L in 2010\u20132015. Data were obtained from national, population-based registers (patient, prescription, income, and laboratory).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We included 11,997 individuals. Acute myocardial infarction, ischemic stroke and stable angina pectoris accounted for 79.6% of the qualifying ASCVD events. At inclusion, 37.2% were in LLT. Mean LDL-C before or during ASCVD hospitalization was 3.1 mmol\/L (120 mg\/dL). LDL-C goal achievement increased within the first two years after inclusion from 40.5% to 50.6%. LLT initiation within the first 90 days increased from 48.6% to 56.0%. Initiation of intensive LLT increased from 9.6% to 32.8%. The largest change in LLT intensity was seen in the period 180 days before to 90 days after discharge with 2.2% in 2010 to 12.1% in 2015.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>LDL-C goal achievement within the first 2 years after inclusion increased from 40.5% in 2010 to 50.6% in 2015. LLT initiation within the first year after inclusion increased, especially for intensive LLT, although only one third initiated intensive LLT in 2015. Despite trends show improvements in LDL-C goal achievement, 49.4% of individuals at very high risk of a CV event did not achieve the LDL-C goal within 2 years after ASCVD hospitalization.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0286376","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:52:34Z","timestamp":1685555554000},"page":"e0286376","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9407-3387","authenticated-orcid":true,"given":"Annette Kj\u00e6r","family":"Ersb\u00f8ll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Skov","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Nybo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M\u00f8ller","family":"Hede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Handberg","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Lytken Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5059-3655","authenticated-orcid":true,"given":"Anders","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"pone.0286376.ref001","unstructured":"World Health Organization. Top 10 causes of death. 2020. http:\/\/www.who.int\/gho\/mortality_burden_disease\/causes_death\/top_10\/en\/ (accessed 23 July 2020)."},{"key":"pone.0286376.ref002","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJMra1201534","article-title":"Measuring the global burden of disease","volume":"369","author":"CJ Murray","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0286376.ref003","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology","volume":"60","author":"LJ Laslett","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"pone.0286376.ref004","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"J Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"pone.0286376.ref005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ehjqcco\/qcy058","article-title":"Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data","volume":"5","author":"M Lindh","year":"2019","journal-title":"Eur Heart J\u2013Qual Care Clin Outcomes"},{"key":"pone.0286376.ref006","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1 Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"BA Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"pone.0286376.ref007","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"AL Catapano","year":"2016","journal-title":"Eur. Heart J"},{"key":"pone.0286376.ref008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur. Heart J"},{"key":"pone.0286376.ref009","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"pone.0286376.ref010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"for the FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"MS Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0286376.ref011","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"GG Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0286376.ref012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-021-01338-y","article-title":"Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets\u2019 attainment in subjects with and without type 2 diabetes","volume":"20","author":"ML Morieri","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0286376.ref013","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies","year":"2019","journal-title":"Atherosclerosis"},{"issue":"11","key":"pone.0286376.ref014","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Y Gong","year":"2021","journal-title":"Clin Cardiol"},{"key":"pone.0286376.ref015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","author":"AK Gitt","year":"2016","journal-title":"Atherosclerosis"},{"key":"pone.0286376.ref016","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5551\/jat.31179","article-title":"Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)","volume":"23","author":"CE Chiang","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"pone.0286376.ref017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2014Findings from the EUROASPIRE IV survey","volume":"246","author":"\u017d Reiner","year":"2016","journal-title":"Atherosclerosis"},{"issue":"11","key":"pone.0286376.ref018","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Y Gong","year":"2021","journal-title":"Clin Cardiol"},{"key":"pone.0286376.ref019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.03.017","article-title":"Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy","volume":"285","author":"V Presta","year":"2019","journal-title":"Atherosclerosis"},{"key":"pone.0286376.ref020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12872-020-01616-9","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study","volume":"20","author":"MS Kristensen","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"pone.0286376.ref021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany","volume":"268","author":"W M\u00e4rz","year":"2018","journal-title":"Atherosclerosis"},{"key":"pone.0286376.ref022","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands","volume":"39","author":"JG Kuiper","year":"2017","journal-title":"Clin Ther"},{"key":"pone.0286376.ref023","doi-asserted-by":"crossref","first-page":"e59309","DOI":"10.1371\/journal.pone.0059309","article-title":"Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999\u20132008 National Health and Nutrition Examination Surveys","volume":"8","author":"MC Tattersall","year":"2013","journal-title":"PLoS ONE"},{"key":"pone.0286376.ref024","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacl.2018.04.007","article-title":"Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service","volume":"12","author":"DG Jr Lamprecht","year":"2018","journal-title":"J Clin Lipidol"},{"key":"pone.0286376.ref025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jjcc.2019.08.012","article-title":"Trends and predictors of high-intensity statin therapy and LDL-C goal achievement among Thai patients with acute coronary syndrome","volume":"75","author":"Y Wongsalap","year":"2020","journal-title":"J Cardiol"},{"key":"pone.0286376.ref026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.amjcard.2014.10.021","article-title":"Frequency of high-risk patients not receiving high-potency statin (from a large managed care database)","volume":"115","author":"F Rodriguez","year":"2015","journal-title":"Am J Cardiol"},{"key":"pone.0286376.ref027","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","article-title":"Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins","volume":"107","author":"KM Fox","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"pone.0286376.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140197","article-title":"Comparison of the Five Danish Regions Regarding Demographic Characteristics, Healthcare Utilization, and Medication Use\u2014A Descriptive Cross-Sectional Study","volume":"10","author":"DP Henriksen","year":"2015","journal-title":"PLoS ONE"},{"key":"pone.0286376.ref029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"E Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"pone.0286376.ref030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"HW Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"pone.0286376.ref031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1403494811405098","article-title":"Danish registers on personal income and transfer payments","volume":"39","author":"M Baadsgaard","year":"2011","journal-title":"Scand J Public Health"},{"key":"pone.0286376.ref032","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bcpt.13167","article-title":"Sixteen Years of Creatinine Measurements Among 460 000 individuals\u2014The Funen Laboratory Cohort (FLaC), a Population\u2010based Pharmacoepidemiological Resource to Study Drug\u2010induced Kidney Disease","volume":"124","author":"DP Henriksen","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"pone.0286376.ref033","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"CB Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"pone.0286376.ref034","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"CP Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0286376.ref035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10654-013-9873-0","article-title":"When the entire population is the sample: strengths and limitations in register-based epidemiology","volume":"29","author":"LC Thygesen","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"pone.0286376.ref036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1403494811399956","article-title":"Introduction to Danish (nationwide) registers on health and social issues: Structure, access, legislation, and archiving","volume":"39","author":"LC Thygesen","year":"2011","journal-title":"Scand J Public Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0286376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:53:24Z","timestamp":1685555604000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0286376"}},"subtitle":[],"editor":[{"given":"Fares","family":"Alahdab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0286376","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}